June 22, 2026 Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
June 22, 2026 Montana-Dakota Utilities Announces Electric Service Agreement with Applied Digital for Proposed AI Factory